Showing 2,676 results

Filters Content type: News, Editors' picks, About HIV Topic: Hepatitis & HIV

Hepatitis A, B and C are viral infections that can damage the liver and cause serious illnesses. Co-infection with HIV and hepatitis B or C is quite common. Safe and effective treatments are available.

Cancer

The connection between Fatty Liver Disease and the Increase in the Rate of Liver Cancer

Editor's pick
AASLD press release
11 November 2012
New & experimental hepatitis C treatment

Boehringer Ingelheim to start late-stage hepatitis C drug trial

Editor's pick
Reuters
11 November 2012
New & experimental hepatitis C treatment

Idenix Reports On IDX719 and IDX184

Editor's pick
Idenix press release
11 November 2012
Hepatitis C transmission & prevention

Hepatitis C-Safeguarding the Medical Injection Process

Editor's pick
HCV New Drugs Research
10 November 2012
People who inject drugs

UK: HPA report found half of people who inject drugs are infected with hepatitis C, one in 100 have HIV

Editor's pick
Health Protection Agency
10 November 2012
Hepatitis C transmission & prevention

Europe Fails to Screen its Population for Hepatitis

Editor's pick
PR Newswire
8 November 2012
Hepatitis C transmission & prevention

UK lags behind Germany France and Slovenia in international index on hepatitis care performance

Editor's pick
Hepatitis C Trust
8 November 2012
New & experimental hepatitis C treatment

Copy of Merck will initiate interferon-free Phase II clinical trials for MK-5172, an investigational, once-daily, oral treatment for chronic hepatitis C virus

Editor's pick
Merck press release
6 November 2012
New & experimental hepatitis C treatment

Merck will initiate interferon-free Phase II clinical trials for MK-5172, an investigational, once-daily, oral treatment for chronic hepatitis C virus

Editor's pick
Merck press release
6 November 2012
Hepatitis C transmission & prevention

Hepatits C could be eliminated from cities, leading specialist says

Editor's pick
GP Online
5 November 2012
New & experimental hepatitis C treatment

Avoiding Missteps When Evaluating New HCV Trial Data

Editor's pick
Clinical Care Options (requires registration)
5 November 2012
Pharmaceutical industry

Gilead and the Pharmasset Deal: Do the Ends Justify the Means?

Editor's pick
PropThink
5 November 2012
Access to healthcare

Hope for hep-c patients: Patients succeed in overturning first ever product patent on medicine in India

Editor's pick
Lawyers' Collective
2 November 2012
Access to healthcare

IPAB revokes patent on Roche Hepatitis C drug

Editor's pick
Hindu Business Line
2 November 2012
Hepatitis C symptoms & diagnosis

African American women with HIV/HCV less likely to die from liver disease

Editor's pick
Science Daily
1 November 2012
New & experimental hepatitis C treatment

Vertex Joins Glaxo, J&J in Testing Hepatitis C Combos

Editor's pick
Bloomberg BusinessWeek
1 November 2012
New & experimental hepatitis C treatment

Achillion Pharma Worthy of New Look - TheStreet.com

Editor's pick
Google Alerts - Hepatitis
31 October 2012
Hepatitis C symptoms & diagnosis

bioMérieux launches antibody test for hepatitis C

Editor's pick
MTBeurope
31 October 2012
New & experimental hepatitis C treatment

BioCryst drops hep C drug on safety issues

Editor's pick
Reuters
31 October 2012
Hepatitis C transmission & prevention

HIV+ People Who Acquire Hepatitis C May Have Impaired HCV-specific Interferon Response

Editor's pick
HIVandHepatitis.com
30 October 2012
Hepatitis C treatment

Antiviral treatment reduces risk of liver cancer in people with hepatitis C-related cirrhosis and fibrosis

News
29 October 2012
Hepatitis C symptoms & diagnosis

Dramatic increase in incidence of liver cancer in HIV-positive people with viral hepatitis

News
29 October 2012
New & experimental hepatitis C treatment

Will Dropping Interferon Be the Magic Bullet for Reducing HCV Mortality?

Editor's pick
Clinical Care Options (requires registration)
26 October 2012
Harm reduction

Hepatitis C curbed by needle exchange but still rampant

Editor's pick
Drug and Alcohol Findings
26 October 2012